Chronic obstructive pulmonary disease (COPD) is a progressive lung
disease which includes emphysema, chronic bronchitis, refractory
asthma, and some forms of bronchiectasis. This disease is
characterized by increasing breathlessness, wheezing, tightness in
chest etc. In the early stages, there may be no symptoms but the
symptoms gradually increases in later stages. Shortness of breath,
chronic cough, fatigue, frequent flu, weight-loss etc. are the
symptoms exhibited in the later stages. Spirometry, chest X-ray,
arterial blood gas test etc. are the common tests for diagnosing
COPD. Smoking, genetic factors and environmental pollution are some
major risk factor that developed chronic obstructive pulmonary
diseases.
Report Overview @
https://www.transparencymarketresearch.com/chronic-obstructive-pulmonary-disease-drugs-market.html
Based on drug type, the chronic obstructive pulmonary diseases market
can be segmented into anticholinergic, oral corticosteroid,
beta2-agonists, phosphodiesterase-4 (PDE4) inhibitors and others
(antibiotic, methylxanthines etc.). Among these, the oral
corticosteroid segment is likely to expand significantly compare to
other drugs owing to extensive uses in the treatment of all types of
chronic obstructive pulmonary diseases. Based on test type, the
chronic obstructive pulmonary diseases drugs market can be classified
as lung functional test, chest x-ray test, CT scan, and others
(arterial blood gas test, genetic test etc.). Among these, the lung
functional test which is also called as spirometry test is expand at
a high growth rate because, the test is convenient, and accurately
measure the lung function and capacity.
Based on application, the chronic obstructive pulmonary diseases
drugs market can be classified into emphysema, chronic bronchitis,
and refractory asthma. The chronic bronchitis segment is expand at a
significant rate due to increasing prevalence’s of the disease and
it provides effective and efficient treatment especially for the
geriatric people. As per the Forum of International Respiratory
Societies (FIRS), chronic obstructive pulmonary diseases affects
more than 200 million individuals worldwide annually and is likewise
considered as one of the main sources of death comprehensively.
Attributable to these disturbing measurements, the utilization of
pulmonary drugs is probably going to pick up force, and thereby the
market will also grow accordingly. . Moreover, the advent of
combination drugs is further projected to propel the growth of the
global chronic obstructive pulmonary diseases drugs market. However,
unknown etiology of chronic obstructive pulmonary diseases in medical
industry and lack of proper awareness about the effect of chronic
obstructive pulmonary diseases would might hinder the growth of the
market.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=36086
In terms of region, the global chronic obstructive pulmonary diseases
drugs market can be segmented into North America, Europe, Asia
Pacific, Latin America and Middle East & Africa. North America
dominates global market followed by Europe due to growing use of the
drugs for treatment of COPD and high awareness regarding treatment.
Increasing environmental pollution, rapidly growing the number
smoker’s and the growing prevalence’s of pulmonary disease are
like to attribute the market of chronic obstructive pulmonary
diseases drugs in Asia Pacific region. Advancements in drug delivery,
increasing per capita income, rising expenditure on personal care and
growing incidences of diseases especially chronic pulmonary diseases
are likely to augment the market for chronic obstructive pulmonary
diseases in Middle East & Africa region during the forecast
period.
Major players operating in the global chronic obstructive pulmonary
diseases market include ., Boehringer Ingelheim GmbH, Teva
Pharmaceutical Industries Ltd., AstraZeneca plc, Novartis AG, Bayer
AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Merck & Co.,
Inc., Actelion Pharmaceuticals, IncSunovion Pharmaceuticals, Inc. and
others.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=36086<ype=S
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment